Lactulose
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Lactulose: From Hepatic Encephalopathy and Constipation to Acute Urate Nephropathy
One-Sentence Summary
Lactulose is a non-absorbable disaccharide, used clinically for hepatic encephalopathy and as a laxative. The TxGNN model predicts it may be effective for acute urate nephropathy, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hepatic encephalopathy and constipation (from the literature; the license data lists no indication text) |
| Predicted New Indication | Acute urate nephropathy |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 licenses (the five listed are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Lactulose is a non-absorbable disaccharide whose efficacy in hepatic encephalopathy and constipation is established, but nothing in the supplied data links it to urate handling or to uric acid-induced kidney injury.
The high score (99.89%) comes only from the knowledge-graph model. No trial or paper supports it, and no plausible mechanism can be drawn from the supplied data. The prediction should be treated as a hypothesis, not as a lead with mechanistic backing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA074712 | KRISTALOSE | Powder, for solution | Cumberland Pharmaceuticals Inc. |
| ANDA209517 | Lactulose | Solution | Chartwell RX, LLC |
| ANDA076645 | Lactulose Solution | Solution | Kesin Pharma Corporation |
| ANDA074712 | Lactulose | Solution | Foxland Pharmaceuticals, Inc. |
| ANDA090502 | Enulose | Solution | Actavis Pharma, Inc. |
These are the 5 main products shown out of 20 licenses. All are oral-type forms (powder for solution and solution).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials, no literature, and no supported mechanism. Evidence level is L5 and the candidate stays at the screening stage (S0).
To proceed, the following is needed:
- A plausible mechanistic rationale linking lactulose to urate-related kidney injury
- Preclinical or observational data for acute urate nephropathy
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications, which are currently unavailable
Note on other predictions for this drug: Obstructive jaundice (rank 3, score 99.53%) has more support. It has one completed Phase 4 trial (NCT01090193) that is a kidney histopathology study with no confirmed lactulose arm, plus about 20 publications, including a randomized study of preoperative lactulose for postoperative renal dysfunction (PMID 2032107). This is evidence level L3, framed as a research question. It is a more promising direction to follow up than the top-ranked prediction.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.